Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BUTRANS vs ANEXSIA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Buprenorphine is a partial mu-opioid receptor agonist and a weak kappa-opioid receptor antagonist. It binds with high affinity to mu-opioid receptors, producing analgesic and opioid effects with a ceiling effect on respiratory depression.
ANEXSIA is a combination of hydrocodone and acetaminophen. Hydrocodone is an opioid agonist that binds to mu-opioid receptors in the central nervous system, altering pain perception and emotional response to pain. Acetaminophen's analgesic mechanism is not fully understood but involves inhibition of COX enzymes in the CNS and modulation of descending serotonergic pathways.
Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate,Treatment of opioid dependence (as part of medication-assisted treatment)
Relief of moderate to moderately severe pain
Apply one BUTRANS (buprenorphine) transdermal system to a clean, dry, non-irritated, and non-hairy area of the chest, back, flank, or upper arm. Initial dose: 5 mcg/h for opioid-naïve patients; titrate based on pain control and tolerability. Maximum dose: 20 mcg/h. Replace every 7 days. Rotate application sites.
50-100 mg orally every 4-6 hours as needed; maximum 400 mg/day.
Terminal half-life: 4-6 hours in healthy adults; prolonged to 12-18 hours in elderly or renal impairment
Terminal elimination half-life is 4-6 hours in adults with normal renal function; prolonged to 12-24 hours in severe renal impairment (Cr Cl <30 m L/min).
Primarily metabolized by CYP3A4 to norbuprenorphine; also undergoes conjugation with glucuronic acid. Norbuprenorphine is active and further glucuronidated.
Hydrocodone is metabolized via CYP2D6 and CYP3A4 to hydromorphone and norhydrocodone. Acetaminophen is primarily metabolized via hepatic glucuronidation and sulfation; a minor pathway via CYP2E1 produces NAPQI, which is detoxified by glutathione.
Renal: 60-70% as unchanged drug and metabolites; biliary/fecal: 20-30%
Approximately 70% renal (unchanged drug and metabolites), 20% biliary/fecal, 10% other.
96% bound primarily to albumin and alpha-1-acid glycoprotein
Approximately 95% bound to plasma albumin and alpha-1-acid glycoprotein.
Vd: 2-5 L/kg, indicating extensive tissue distribution
0.2-0.4 L/kg, indicating limited extravascular distribution primarily confined to plasma and interstitial fluid.
Transdermal: 15-25%; buccal: 60-70%
Oral: 80-90%; Intramuscular: 90-100%; Rectal: 70-80%.
No dose adjustment required for mild to moderate renal impairment (Cr Cl ≥30 m L/min). For severe renal impairment (Cr Cl <30 m L/min), use with caution and consider starting at the lowest dose (5 mcg/h) with close monitoring for adverse effects.
GFR 30-89 m L/min: no adjustment; GFR 15-29 m L/min: 50% dose reduction; GFR <15 m L/min: avoid use.
Child-Pugh Class A: No dose adjustment. Child-Pugh Class B: Start at the lowest dose (5 mcg/h) and titrate cautiously; consider reducing dose by 50%. Child-Pugh Class C: Avoid use due to increased risk of toxicity.
Child-Pugh A: no adjustment; Child-Pugh B: 50% dose reduction; Child-Pugh C: avoid use.
Not recommended for use in pediatric patients under 18 years of age due to lack of safety and efficacy data.
1-2 mg/kg/dose orally every 6 hours; maximum 6 mg/kg/day.
Initiate at the lowest dose (5 mcg/h) and titrate slowly with careful monitoring for respiratory depression, sedation, and falls. Consider age-related reductions in renal and hepatic function.
Initiate at 25 mg every 6 hours; increase cautiously; monitor renal function.
Risk of respiratory depression, addiction, abuse, and misuse; risk of neonatal opioid withdrawal syndrome; risk of potentially fatal respiratory depression when used with benzodiazepines or other CNS depressants; and risk of life-threatening respiratory depression in children with accidental ingestion.
Addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion; neonatal opioid withdrawal syndrome; risks from concomitant use with benzodiazepines or other CNS depressants; hepatotoxicity from acetaminophen.
Addiction, abuse, and misuse; respiratory depression; neonatal opioid withdrawal syndrome; risk with benzodiazepines or other CNS depressants; severe hypotension; gastrointestinal obstruction; seizures; biliary tract disease; use in elderly and debilitated patients; hepatic impairment; renal impairment; pregnancy; lactation.
Risk of respiratory depression, especially in elderly or debilitated patients; adrenal insufficiency; severe hypotension; seizures; opioid-induced hyperalgesia; acetaminophen hepatotoxicity (avoid exceeding 4 g/day); serotonin syndrome if used with serotonergic agents.
Hypersensitivity to buprenorphine; significant respiratory depression; acute or severe bronchial asthma; known or suspected gastrointestinal obstruction; concurrent use of monoamine oxidase inhibitors (MAOIs) or within 14 days of such therapy.
Hypersensitivity to hydrocodone or acetaminophen; significant respiratory depression; acute or severe bronchial asthma in an unmonitored setting; known or suspected GI obstruction; severe hepatic impairment; concomitant use of MAOIs or within 14 days.
Avoid grapefruit and grapefruit juice as they inhibit CYP3A4, potentially increasing buprenorphine levels. No other significant food interactions documented.
Avoid alcohol; may increase risk of hepatotoxicity and GI bleeding. Limit caffeine intake from coffee, tea, cola, or energy drinks due to added caffeine content. High-fat meals may delay absorption; take on empty stomach for faster onset if tolerated.
First trimester: Inadequate human data; animal studies show no teratogenicity at clinically relevant doses. Second/third trimester: Prolonged use can cause neonatal opioid withdrawal syndrome (NOWS); avoid chronic use near term due to risk of respiratory depression. Generally, buprenorphine is considered lower risk than full agonists but still requires careful risk-benefit assessment.
First trimester: Data are limited; no increased risk of major malformations reported in small studies. Second and third trimesters: Associated with premature closure of the ductus arteriosus and oligohydramnios due to fetal renal effects; avoid use after 30 weeks gestation.
Buprenorphine is excreted into breast milk. M/P ratio approximately 0.3 (range 0.1-0.6). Relative infant dose about 1-2% of maternal weight-adjusted dose. Monitor infant for sedation, respiratory depression, and withdrawal if breastfeeding is initiated or discontinued. Generally compatible with breastfeeding in stable patients.
Excreted into breast milk in low concentrations (M/P ratio not established). Not recommended during breastfeeding due to potential for adverse effects in the infant, including renal impairment and gastrointestinal bleeding.
No routine dose adjustment recommended. However, increased clearance in pregnancy may require dose titration based on clinical response. Monitor for withdrawal symptoms as pregnancy progresses; dose may need to be increased. Postpartum, dose may need to be reduced due to restored clearance.
Dose adjustment not generally required; however, due to increased renal clearance in pregnancy, shortened dosing intervals may be necessary for sustained efficacy. Use lowest effective dose for shortest duration.
BUTRANS (buprenorphine transdermal system) is a Schedule III partial mu-opioid agonist used for chronic pain. Do not apply to irritated skin; rotate application sites to minimize skin reactions. Onset of analgesia is delayed (12-24 hours), so titrate with immediate-release analgesics as needed. Avoid concurrent use with full mu-opioid agonists (e.g., morphine) due to risk of precipitated withdrawal. The 5, 7.5, 10, 15, and 20 mcg/h patches are approved; 20 mcg/h is the maximum single dose. Reserve for patients tolerant to around-the-clock opioids (≥30 mg oral morphine equivalents/day). Monitor for respiratory depression (less than full agonists, but still a risk) and serotonin syndrome with other serotonergic agents.
ANEXSIA is a combination analgesic containing paracetamol, ibuprofen, and caffeine. It is contraindicated in patients with active peptic ulcer disease, severe hepatic impairment, or hypersensitivity to NSAIDs. Avoid concurrent use with other NSAIDs or paracetamol-containing products. Monitor renal function in elderly or dehydrated patients. Caffeine may exacerbate anxiety or insomnia.
Apply the patch to clean, dry, hairless skin on the upper arm, chest, back, or side of the chest. Remove immediately if it falls off.,Wear the patch for 7 days; replace with a new patch at the same time of day. Do not cut or damage the patch.,Avoid exposure to direct heat (heating pads, saunas, hot tubs, prolonged sun) as it increases absorption and overdose risk.,Do not drink alcohol while using Butrans; it can cause dangerous side effects.,Keep all patches away from children and pets; used patches should be folded and flushed down the toilet immediately.,Do not stop abruptly or change dose without consulting your doctor; withdrawal may occur.,Common side effects include nausea, constipation, headache, and application site redness.
Do not exceed recommended dose; overdosage of paracetamol can cause liver damage.,Take with food or milk to reduce gastrointestinal upset.,Avoid alcohol while taking this medication to reduce risk of liver toxicity and GI bleeding.,Discontinue use and consult if signs of allergic reaction, GI bleeding, or liver problems occur.,Caffeine may cause nervousness, insomnia, or increased heart rate; limit caffeine-containing foods and beverages.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BUTRANS vs ANEXSIA, answered by our medical review team.
BUTRANS is a Opioid Analgesic that works by Buprenorphine is a partial mu-opioid receptor agonist and a weak kappa-opioid receptor antagonist. It binds with high affinity to mu-opioid receptors, producing analgesic and opioid effects with a ceiling effect on respiratory depression.. ANEXSIA is a Opioid Analgesic Combination that works by ANEXSIA is a combination of hydrocodone and acetaminophen. Hydrocodone is an opioid agonist that binds to mu-opioid receptors in the central nervous system, altering pain perception and emotional response to pain. Acetaminophen's analgesic mechanism is not fully understood but involves inhibition of COX enzymes in the CNS and modulation of descending serotonergic pathways.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BUTRANS and ANEXSIA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BUTRANS is: Apply one BUTRANS (buprenorphine) transdermal system to a clean, dry, non-irritated, and non-hairy area of the chest, back, flank, or upper arm. Initial dose: 5 mcg/h for opioid-naïve patients; titrate based on pain control and tolerability. Maximum dose: 20 mcg/h. Replace every 7 days. Rotate application sites.. The standard adult dose of ANEXSIA is: 50-100 mg orally every 4-6 hours as needed; maximum 400 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BUTRANS and ANEXSIA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BUTRANS is classified as Category C. First trimester: Inadequate human data; animal studies show no teratogenicity at clinically relevant doses. Second/third trimester: Prolonged use can cause neonatal opioid withdraw. ANEXSIA is classified as Category C. First trimester: Data are limited; no increased risk of major malformations reported in small studies. Second and third trimesters: Associated with premature closure of the ductus . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.